Key facts
- This page summarizes Michael B. Mason's Form 4 filing for ELI LILLY & Co (LLY).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Feb 2023, 15:49.
Michael B. Mason - 10 Feb 2023 Form 4 Insider Report for ELI LILLY & Co (LLY)
- Reporting relationship
- EVP & Pres., Lilly Diabetes
- Issuer ticker
- LLY
- Reported as of
- 10 Feb 2023
- Net transaction value
- +$2,768,898
- SEC form
- 4
- Accepted by SEC
- 14 Feb 2023, 15:49:07 UTC
- Prior SEC filing
- 03 Feb 2023
- Next SEC filing
- 02 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Groff for Michael B. Mason, pursuant to authorization on file
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael B. Mason filed Form 4 for ELI LILLY & Co (LLY) on 14 Feb 2023.
Change
- Previous filing in this sequence was filed on 03 Feb 2023.
- Current net transaction value: +$2,768,898.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LLY
transaction
Common Stock
Award
- Transaction value
- $2,768,898
- Shares
- +8,023
- Change %
- +26%
- Price
- $345.12
- Shares after
- 39,284
- Date
- 10 Feb 2023
- Ownership
- Direct
LLY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 957
- Date
- 10 Feb 2023
- Ownership
- 401(k)
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LLY
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +3,490
- Change %
- Price
- $0.000000
- Shares after
- 3,490
- Date
- 10 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,490
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.